Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Ibutamoren, scientifically known as MK-677, is a potent oral growth hormone secretagogue that mimics the action of ghrelin, the "hunger hormone." Its chemical identity is defined by the molecular formula C23H28N4O2 and it carries the CAS registry number 159200-17-6. Structurally, it is a non-peptide compound belonging to the class of mibolerone derivatives, specifically designed to stimulate the pituitary gland to increase endogenous production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Unlike injectable synthetic hormones, Ibutamoren offers high bioavailability when taken orally, making it a popular choice in research and off-label therapeutic contexts.
The primary utility of Ibutamoren lies in its ability to boost GH levels naturally without exogenous administration. This mechanism has led to significant interest in medical fields for treating muscle wasting conditions associated with aging or chronic diseases like HIV/AIDS and kidney failure. By elevating IGF-1, it promotes protein synthesis, enhances nitrogen retention, and accelerates tissue repair, which can result in increased lean muscle mass and improved bone density. Furthermore, users often report benefits regarding sleep quality and recovery times, attributed to the deepened slow-wave sleep phases induced by elevated GH pulses.
In the fitness and bodybuilding communities, this compound is frequently utilized during cutting cycles to preserve muscle mass while reducing fat, as well as during bulking phases to support rapid hypertrophy. It also aids in skin elasticity and wound healing due to collagen stimulation. However, potential side effects include water retention, increased appetite, numbness, and transient insulin resistance, necessitating careful monitoring. While widely available for research purposes, regulatory status varies globally, and it is not approved by major health agencies like the FDA for general human consumption outside specific clinical trials. Consequently, prospective users must exercise caution, understanding that long-term safety data remains limited compared to established pharmaceuticals.